William Garrett Gray
Net Worth

Last updated:

What is William Garrett Gray net worth?

The estimated net worth of Mr. William Garrett Gray is at least $7,351,988 as of 18 Dec 2024. He owns shares worth $4,399,532 as insider, has earned $1,472,456 from insider trading and has received compensation worth at least $1,480,000 in Checkpoint Therapeutics, Inc..

What is the salary of William Garrett Gray?

Mr. William Garrett Gray salary is $296,000 per year as Chief Financial Officer, Corporation Sec. & Treasurer in Checkpoint Therapeutics, Inc..

How old is William Garrett Gray?

Mr. William Garrett Gray is 38 years old, born in 1987.

What stocks does William Garrett Gray currently own?

As insider, Mr. William Garrett Gray owns shares in one company:

Company Title Shares Price per share Total value
Checkpoint Therapeutics, Inc. (CKPT) Chief Financial Officer, Corporation Sec. & Treasurer 1,032,754 $4.26 $4,399,532

What does Checkpoint Therapeutics, Inc. do?

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

William Garrett Gray insider trading

Checkpoint Therapeutics, Inc.

Mr. William Garrett Gray has made 13 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 268,432 units of CKPT stock worth $1,076,412 on 18 Dec 2024.

The largest trade he's ever made was exercising 268,432 units of CKPT stock on 18 Dec 2024. As of 18 Dec 2024 he still owns at least 1,032,754 units of CKPT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
COMMON STOCK 268,432 $4.01 $1,076,412
Sale
Common Stock 13,038 $2.06 $26,858
Sale
Common Stock 2,035 $2.07 $4,212
Sale
Common Stock 4,115 $1.95 $8,024
Sale
Common Stock 3,591 $5 $17,955
Sale
Common Stock 1,914 $4.66 $8,919
Sale
Common Stock 3,154 $4.79 $15,108
Sale
Common Stock 1,858 $6.75 $12,540
Sale
COMMON STOCK 38,197 $1.89 $72,307
Sale
COMMON STOCK 37,063 $2.51 $92,954
Sale
COMMON STOCK 26,320 $3.66 $96,331
Sale
COMMON STOCK 2,406 $2.79 $6,713
Sale
COMMON STOCK 17,104 $2 $34,122

Checkpoint Therapeutics key executives

Checkpoint Therapeutics, Inc. executives and other stock owners filed with the SEC: